Clinical trials: Ischemic Stroke
Cerebral Infarction, Brain Ischemia
Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke
Based on previous studies comparing Duteplase[a recombinant tissue plasminogen activator (rt-PA) very similar to alteplase] doses, we performed a clinical trial with 0.6mg/kg, which is lower than the internationally approved…
- Trial name
- NCT00147316
- Testing
- Alteplase
- Where
- Japan
- Volunteers
- 103 people
- Sponsor
- Tanabe Pharma Corporation
Atrial Fibrillation
Evaluation of the Next Generation WATCHMAN LAA Closure Technology in Non-Valvular AF Patients (EVOLVE)
This study will evaluate the next generation WATCHMAN Left Atrial Appendage (LAA) Closure Device as implanted in patients with non-valvular atrial fibrillation (AF) with a CHADS2 stroke risk stratification score of 1 or greater.
- Trial name
- EVOLVE (NCT01196897)
- Testing
- WATCHMAN LAA Closure Technology (Gen 4.0)
- Where
- 3 sites in Czechia, Germany
- Volunteers
- 69 people
- Sponsor
- Boston Scientific Corporation
Stroke, Stroke, Acute
Safety Evaluation of the ReWalk ReStore Device in Subjects With Mobility Impairments Due to Stroke
A multi-site, interventional, non-comparative, single-arm trial to evaluate the safety of the ReWalk ReStore device in subjects with hemiplegia/hemiparesis due to ischemic or hemorrhagic stroke.
- Conditions
- Stroke, Stroke, Acute, Stroke Hemorrhagic, Hemiparesis
- Trial name
- NCT03499210
- Testing
- ReWalk ReStore device
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- ReWalk Robotics, Inc.
Chronic Ischemic Stroke
A Study of Modified Stem Cells in Stable Ischemic Stroke
The primary purpose of the clinical study is to determine the safety of a modified stem cell SB623 when administered to chronic, stable ischemic stroke patients.
- Trial name
- NCT01287936
- Testing
- SB623
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- SanBio, Inc.
Left Atrial Appendage Exclusion
AtriCure Exclusion of the LAA in Patients Undergoing Concomitant Cardiac Surgery
Prospective, non-randomized trial to evaluate the safety and efficacy of the LAA Exclusion Device (Clip) for the exclusion of the LAA via epicardial tissue approximation.
- Trial name
- EXCLUDE (NCT00779857)
- Testing
- AtriCure LAA Exclusion System
- Where
- 7 sites in United States
- Volunteers
- 70 people
- Sponsor
- AtriCure, Inc.
Cerebrovascular Accident
Safety Study of a Recombinant Human Plasminogen Activator to Treat Acute Ischemic Stroke.
To evaluate the safety profiles of HTU-PA in patients with acute ischemic stroke.
- Trial name
- NCT00418275
- Testing
- Recombinant Human Plasminogen Activator (HTUPA)
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Global Biotech
Ischemic Stroke
Strategy for Improving Stroke Treatment Response
SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in…
- Trial name
- SISTER (NCT05948566)
- Testing
- TS23
- Where
- 52 sites in United States
- Volunteers
- 300 people
- Sponsor
- Translational Sciences, Inc.
Cerebral Infarction
Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology Study
Sarpogrelate is an antiplatelet agent that decreases 5-hydroxytryptamine( 5-HT )levels in platelets via blockade of 5-HT2 receptors, has been used in atherosclerotic peripheral arterial disease.
- Trial name
- NCT00147303
- Testing
- MCI-9042
- Volunteers
- 46 people
- Sponsor
- Tanabe Pharma Corporation
Acute Ischemic Stroke
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
The purpose of this trial is to determine if intravenous administration of the metal ion trapping agent DP-b99 up to 9 hours following acute ischemic stroke onset, and then for 3 additional days (4 consecutive days in total) is…
- Trial name
- MACSI (NCT00893867)
- Testing
- DP-b99
- Where
- 154 sites in United States, Austria and 16 more
- Volunteers
- 446 people
- Sponsor
- D-Pharm Ltd.
Stroke, Acute, COVID-19
EPISODE-PS-COVID: hEad Pulse for Ischemic StrOke DEtection Prehospital Study During the COVID-19 Pandemic ( EPISODEPSCOVID )
Prehospital providers encounter patients with suspected stroke frequently. Stroke and COVID-19 are related potentially putting these healthcare workers at risk of COVID-19 infection.
- Trial name
- EPISODE-PH-COV (NCT04445493)
- Testing
- MindRhythm Harmony
- Where
- United States
- Volunteers
- 486 people
- Sponsor
- MindRhythm, Inc.
Carotid Artery Disease, Stroke Prevention
Diffusion Weighted-MRI Based Evaluation of the Effectiveness of Endovascular Clamping During Carotid Artery Stenting With the Mo.Ma Device.
The purpose of this study is to detect new ischemic lesions after carotid artery stenting (with the Cristallo Ideale stent), in patients with high grade carotid artery stenosis, by diffusion-weighted magnetic resonance imaging…
- Trial name
- DESERVE (NCT00798512)
- Testing
- Carotid artery stenting
- Where
- 6 sites in Germany, Italy and 1 more
- Volunteers
- 127 people
- Sponsor
- Invatec S.p.A.
Stroke
Niche Trial: Navigated Inhibitory rTMS to Contralesional Hemisphere Trial
A pivotal, prospective, multi-center, randomized, controlled, double-blinded study combining active Nexstim NBS-guided 1Hz rTMS or sham-rTMS targeting the healthy hemisphere with standardized task oriented rehabilitation will be…
- Trial name
- NICHE (NCT02089464)
- Testing
- NBS-guided rTMS, Task oriented rehabilitation
- Where
- 12 sites in United States
- Volunteers
- 199 people
- Sponsor
- Nexstim Ltd
Atherosclerosis, Cardiovascular Disease
A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease
The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.
- Conditions
- Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
- Trial name
- HEART-3 (NCT07839936)
- Testing
- VERVE-102
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Verve Therapeutics, Inc.
Ischemic Motor Stroke, Chronic
Intracerebral Transplantation of Neural Stem Cells for the Treatment of Ischemic Stroke
The study is to determine the safety of human neural stem cell transplantation for the treatment of paralysis and related symptoms due to chronic motor stroke and to determine the maximum tolerated dose.
- Trial name
- NCT03296618
- Testing
- NSI-566
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Suzhou Neuralstem Biopharmaceuticals
Acute Ischemic Stroke
Safety Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke
The primary purpose of the study is to determine whether carbamylated erythropoietin (CEPO) is a safe treatment for patients who have suffered an acute ischemic stroke.
- Trial name
- NCT00756249
- Testing
- Lu AA24493 (CEPO)
- Where
- 5 sites in Finland, France and 3 more
- Volunteers
- 16 people
- Sponsor
- H. Lundbeck A/S
Acute Ischemic Stroke, AIS
A Phase I Trial of Umbilical Cord Mesenchymal Stromal Cells for Acute Ischemic Stroke
Study Methods: The trial consists of two phases, both including a placebo control. Phase Ia (single-dose, dose-escalation): Three dose groups (low, medium, high) are set.
- Trial name
- NCT07628933
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells Injection
- Where
- China
- Volunteers
- 35 people
- Sponsor
- BOE Technology Group Co., Ltd.
Ischemic Stroke
Augmenting Cerebral Blood Flow to Preserve the Penumbra Trial
The primary objective of the study is to demonstrate that SPG (Sphenopalatine Ganglion) stimulation started within 6 hours from stroke onset slows the expansion of the infarct core volume in acute ischemic stroke.
- Trial name
- ImpACT-P (NCT04014621)
- Testing
- SPG stimulation
- Where
- 4 sites in Georgia
- Volunteers
- 100 people
- Sponsor
- BrainsGate
Acute Ischemic Stroke
Study Evaluating Single Ascending Doses Of ILS-920
This is a first-in-human study of ILS-920. This study will provide an initial assessment of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ILS-920 after administration of ascending single…
- Trial name
- NCT00827190
- Testing
- ILS-920
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Cardiovascular Disease and Lipoprotein(a)
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
This open-label extension study provides post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301).
- Trial name
- NCT07517263
- Testing
- Pelacarsen (TQJ230)
- Where
- 646 sites in United States, Argentina and 38 more
- Volunteers
- 5,700 people
- Sponsor
- Novartis Pharmaceuticals
Ischemic Symptoms, Cerebral Infarction
Pletaal SR Post Marketing Observational Study
This is a Post Marketing Observational Study of cilostazol (Pletaal® SR capsule). As this study is observational in nature to collect the safety data after administrating the Pletaal SR capsule, from baseline to 16 weeks.
- Trial name
- PLTSRPMOS (NCT01782833)
- Testing
- This is Non-interventional study
- Where
- 4 sites in South Korea
- Volunteers
- 3,635 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.